Coherus Oncology (CHRS) Return on Sales (2013 - 2026)

Coherus Oncology (CHRS) has 14 years of Return on Sales data on file, last reported at 0.0% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales rose 1.0% year-over-year to 0.0%; the trailing twelve-month figure through Mar 2026 stood at 0.08% (up 6.0% YoY), and the FY2025 full-year result was 0.08%, down 1.0% from the prior year.
• Return on Sales slipped to 0.0% in Q1 2026, from 0.01% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.74% in Q1 2024 to a low of 0.02% in Q1 2023.
• A 5-year average of 0.06% and a median of 0.01% in 2024 frame the typical range for Return on Sales.
• Across the five-year window, Return on Sales soared 76 bps in 2024 and slumped 75 bps in 2025, its largest moves.
• Tracing CHRS's Return on Sales over 5 years: stood at 0.01% in 2022, then jumped by 33 bps to 0.01% in 2023, then soared by 32 bps to 0.01% in 2024, then surged by 215 bps to 0.01% in 2025, then tumbled by 117 bps to 0.0% in 2026.
• Business Quant data shows CHRS's Return on Sales at 0.0% in Q1 2026, 0.01% in Q4 2025, and 0.01% in Q3 2025.